This study is testing a new approach to prevent rejection after a heart transplant. It's comparing the standard treatment, which includes tacrolimus, with a regimen that uses belatacept (NULOJIX®) and gradually reduces tacrolimus over nine months. Both groups will also receive mycophenolate mofetil/sodium (CellCept® or Myfortic®). The main goal is to see if belatacept is safe and effective at preventing acute cellular rejection (ACR), which is when your body's immune system attacks the new heart, or other serious problems like re-transplantation or death. You may be able to join if you are between 18 and 71 years old, are receiving your first heart transplant, and have a specific virus called Epstein-Barr Virus (EBV) in your system. The study plans to enroll 66 participants.

Study design

This is a Phase 2, multi-center study where 66 heart transplant recipients will be randomly assigned to one of two treatment groups: standard care or a belatacept-based regimen.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from the time they are randomly assigned to a treatment group until 18 months after their transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.